Kreutz Susanne, Koch Marco, Ghadban Chalid, Korf Horst-Werner, Dehghani Faramarz
Dr. Senckenbergische Anatomie, Institut für Anatomie 2, Johann Wolfgang Goethe-Universität Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany.
Exp Neurol. 2007 Jan;203(1):246-57. doi: 10.1016/j.expneurol.2006.08.010. Epub 2006 Sep 27.
Cannabinoids (CBs) are attributed neuroprotective effects in vivo. Here, we determined the neuroprotective potential of CBs during neuronal damage in excitotoxically lesioned organotypic hippocampal slice cultures (OHSCs). OHSCs are the best characterized in vitro model to investigate the function of microglial cells in neuronal damage since blood-borne monocytes and T-lymphocytes are absent and microglial cells represent the only immunocompetent cell type. Excitotoxic neuronal damage was induced by NMDA (50 microM) application for 4 h. Neuroprotective properties of 9-carboxy-11-nor-delta-9-tetrahydrocannabinol (THC), N-arachidonoylethanolamide (AEA) or 2-arachidonoylglycerol (2-AG) in different concentrations were determined after co-application with NMDA by counting degenerating neurons identified by propidium iodide labeling (PI(+)) and microglial cells labeled by isolectin B(4) (IB(4)(+)). All three CBs used significantly decreased the number of IB(4)(+) microglial cells in the dentate gyrus but the number of PI(+) neurons was reduced only after 2-AG treatment. Application of AM630, antagonizing CB2 receptors highly expressed by activated microglial cells, did not counteract neuroprotective effects of 2-AG, but affected THC-mediated reduction of IB(4)(+) microglial cells. Our results indicate that (1) only 2-AG exerts neuroprotective effects in OHSCs; (2) reduction of IB(4)(+) microglial cells is not a neuroprotective event per se and involves other CB receptors than the CB2 receptor; (3) the discrepancy in the neuroprotective effects of CBs observed in vivo and in our in vitro model system may underline the functional relevance of invading monocytes and T-lymphocytes that are absent in OHSCs.
大麻素(CBs)在体内具有神经保护作用。在此,我们确定了CBs在兴奋性毒性损伤的器官型海马脑片培养物(OHSCs)神经元损伤过程中的神经保护潜力。OHSCs是研究小胶质细胞在神经元损伤中功能的最佳体外模型,因为不存在血源性单核细胞和T淋巴细胞,且小胶质细胞是唯一具有免疫活性的细胞类型。通过应用50微摩尔的N-甲基-D-天冬氨酸(NMDA)4小时诱导兴奋性毒性神经元损伤。在与NMDA共同应用后,通过计数经碘化丙啶标记(PI(+))鉴定的退化神经元和经异凝集素B(4)(IB(4)(+))标记的小胶质细胞,确定不同浓度的9-羧基-11-去甲-δ-9-四氢大麻酚(THC)、N-花生四烯酰乙醇胺(AEA)或2-花生四烯酰甘油(2-AG)的神经保护特性。所使用的所有三种CBs均显著减少了齿状回中IB(4)(+)小胶质细胞的数量,但仅在2-AG处理后PI(+)神经元的数量才减少。应用AM630拮抗活化小胶质细胞高表达的CB2受体,并未抵消2-AG的神经保护作用,但影响了THC介导的IB(4)(+)小胶质细胞数量的减少。我们的结果表明:(1)仅2-AG在OHSCs中发挥神经保护作用;(2)IB(4)(+)小胶质细胞数量的减少本身并非神经保护事件,且涉及除CB2受体之外的其他CB受体;(3)在体内和我们的体外模型系统中观察到的CBs神经保护作用的差异可能突出了OHSCs中不存在的侵入性单核细胞和T淋巴细胞的功能相关性。